Pathology: mGC or mGEJC - L1 - HER2 neg/PDL1 positive; mGC or mGEJC - L1 - HER2 negative; mGC or mGEJC - L2 - all population;
mGC or mGEJC - L1 - HER2 neg/PDL1 positive | mGC or mGEJC - L1 - HER2 negative | mGC or mGEJC - L2 - all population | |||
CheckMate 649 (PDL1 CPS>1), 2021 | CheckMate 649 (PDL1 CPS>5), 2021 | CheckMate 649, 2021 | ATTRACTION-2 (Kang), 2017 | ||
nivolumab plus SoC | 3 | T1 | T1 | T1 | |
nivolumab alone | 1 | T1 | |||
Standard of Care (SoC) | 0 | T0 | T0 | T0 | |
placebo | 0 | T0 |